Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Stem cells

REGENT trial—the end of cell therapy for MI?

Nature Reviews Cardiology volume 6, pages 567–568 (2009)Cite this article

Unselected bone-marrow-derived mononuclear cells seem to improve left ventricular function and perhaps short-term clinical outcomes for patients with acute myocardial infarction. The REGENT trial aimed to elucidate whether infusion of selected hematopoetic progenitor cells increases this effect in patients with large infarcts and attenuated left ventricular ejection fraction.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Asahara, T. et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85, 221–228 (1999).

    Article  CAS  Google Scholar 

  2. Tendera, M. et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur. Heart J. 30, 1313–1321 (2009).

    Article  Google Scholar 

  3. Schächinger, V. et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355, 1210–1221 (2006).

    Article  Google Scholar 

  4. Lunde, K. et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med. 355, 1199–1209 (2006).

    Article  CAS  Google Scholar 

  5. Meyer, G. P. et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113, 1287–1294 (2006).

    Article  Google Scholar 

  6. Martin-Rendon, E. et al. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur. Heart J. 29, 1807–1818 (2008).

    Article  CAS  Google Scholar 

  7. Wojakowski, W. et al. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 110, 3213–3220 (2004).

    Article  CAS  Google Scholar 

  8. Ripa, R. S. et al. Short- and long-term changes in myocardial function, morphology, edema, and infarct mass after ST-segment elevation myocardial infarction evaluated by serial magnetic resonance imaging. Am. Heart J. 154, 929–936 (2007).

    Article  Google Scholar 

  9. Zohlnhofer, D. et al. Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. J. Am. Coll. Cardiol. 51, 1429–1437 (2008).

    Article  Google Scholar 

  10. Schächinger, V. et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur. Heart J. 27, 2775–2783 (2006).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Physiology and Nuclear Medicine, Frederiksberg Hospital, Copenhagen University Hospital, and Faculty of Health Sciences, University of Copenhagen, Denmark

    Rasmus S. Ripa

  2. Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen University Hospital, and Faculty of Health Sciences, University of Copenhagen, Denmark

    Jens Kastrup

Authors
  1. Rasmus S. Ripa
    View author publications

    Search author on:PubMed Google Scholar

  2. Jens Kastrup
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Jens Kastrup.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ripa, R., Kastrup, J. REGENT trial—the end of cell therapy for MI?. Nat Rev Cardiol 6, 567–568 (2009). https://doi.org/10.1038/nrcardio.2009.137

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nrcardio.2009.137

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing